BR112018076443A2 - formas cristalinas de um composto de triazolopirimidina - Google Patents

formas cristalinas de um composto de triazolopirimidina

Info

Publication number
BR112018076443A2
BR112018076443A2 BR112018076443-4A BR112018076443A BR112018076443A2 BR 112018076443 A2 BR112018076443 A2 BR 112018076443A2 BR 112018076443 A BR112018076443 A BR 112018076443A BR 112018076443 A2 BR112018076443 A2 BR 112018076443A2
Authority
BR
Brazil
Prior art keywords
crystalline forms
triazolopyrimidine compound
triazolopyrimidine
compound
dysfunction
Prior art date
Application number
BR112018076443-4A
Other languages
English (en)
Inventor
Liu Bo
Huang Ying
Mao Liang
Wang Long
Murlidhar Waykole Liladhar
Zhang Lijun
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112018076443A2 publication Critical patent/BR112018076443A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

a presente invenção refere-se a formas cristalinas de um composto de triazolopirimidina, que é útil para tratamento de uma doença ou disfunção mediada por prc2.
BR112018076443-4A 2016-06-20 2017-06-19 formas cristalinas de um composto de triazolopirimidina BR112018076443A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/086350 2016-06-20
CN2016086350 2016-06-20
PCT/CN2017/089003 WO2017219948A1 (en) 2016-06-20 2017-06-19 Crystalline forms of triazolopyrimidine compound

Publications (1)

Publication Number Publication Date
BR112018076443A2 true BR112018076443A2 (pt) 2019-04-09

Family

ID=60783815

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076443-4A BR112018076443A2 (pt) 2016-06-20 2017-06-19 formas cristalinas de um composto de triazolopirimidina

Country Status (14)

Country Link
US (2) US11091489B2 (pt)
EP (1) EP3472168B1 (pt)
JP (1) JP7042812B2 (pt)
KR (1) KR102519922B1 (pt)
CN (1) CN109563100B (pt)
AU (1) AU2017282871B2 (pt)
BR (1) BR112018076443A2 (pt)
CA (1) CA3027246A1 (pt)
CL (2) CL2018003734A1 (pt)
IL (1) IL263429B (pt)
MX (1) MX2018016331A (pt)
RU (1) RU2754856C2 (pt)
SA (1) SA518400704B1 (pt)
WO (1) WO2017219948A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TWI763641B (zh) 2015-11-19 2022-05-11 美商英塞特公司 作為免疫調節劑之雜環化合物
MA55194A (fr) 2015-12-22 2022-05-04 Incyte Corp Composés hétérocycliques en tant qu'immunomodulateurs
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
MA45116A (fr) 2016-05-26 2021-06-02 Incyte Corp Composés hétérocycliques comme immunomodulateurs
UA125391C2 (uk) 2016-06-20 2022-03-02 Інсайт Корпорейшн Гетероциклічні сполуки як імуномодулятори
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
HRP20221216T1 (hr) 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
ES2934230T3 (es) 2016-12-22 2023-02-20 Incyte Corp Derivados de benzooxazol como inmunomoduladores
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4043466A1 (en) 2018-01-31 2022-08-17 Mirati Therapeutics, Inc. Prc2 inhibitors
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
PE20211911A1 (es) 2018-03-30 2021-09-28 Incyte Corp Compuestos heterociclicos como inmunomoduladores
MD3790877T2 (ro) 2018-05-11 2023-08-31 Incyte Corp Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
KR20220051226A (ko) * 2019-08-22 2022-04-26 블루레이 테라퓨틱스 (상하이) 컴퍼니 리미티드 아자헤테로아릴 화합물 및 이의 용도
KR20220075382A (ko) 2019-09-30 2022-06-08 인사이트 코포레이션 면역조절제로서의 피리도[3,2-d]피리미딘 화합물
CN110796297B (zh) * 2019-10-21 2020-11-10 浙江大学 一种基于平衡度方差和可靠度的电力***结构优化方法
US20230028221A1 (en) * 2019-11-01 2023-01-26 Shanghaitech University Eed inhibitor, and preparation method therefor and use thereof
AU2020385113A1 (en) 2019-11-11 2022-05-19 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
AU2021281123A1 (en) * 2020-05-28 2023-02-09 Novartis Ag Dosing regimens for N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-C]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating PRC2-mediated diseases or disorders
CN114426541B (zh) * 2020-10-29 2023-06-30 成都先导药物开发股份有限公司 氮杂芳基化合物及其用途
CA3200844A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
AU2021381664A1 (en) 2020-11-20 2023-06-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による関節炎の治療
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
CZ303815B6 (cs) 2000-07-19 2013-05-15 Warner-Lambert Company Derivát O-substituovaného esteru 4-jodfenylaminobenzhydroxamové kyseliny a farmaceutický prípravek s jeho obsahem
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
ES2555307T3 (es) 2002-03-08 2015-12-30 Eisai R&D Management Co., Ltd. Compuestos macrocíclicos útiles como agentes farmacéuticos
DOP2003000613A (es) 2002-03-13 2003-09-30 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole derivatives as mek inhibitors)
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
JP5160885B2 (ja) 2004-06-01 2013-03-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 再構成ヒストンメチルトランスフェラーゼ複合体及びそのモジュレーターの識別方法
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
AU2006272837B2 (en) 2005-07-21 2012-08-23 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of MEK
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2041575A2 (en) 2006-03-31 2009-04-01 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
ES2585902T3 (es) * 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
WO2008083251A2 (en) 2006-12-27 2008-07-10 Usc Stevens - University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
MX338504B (es) 2007-09-12 2016-04-20 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
US20110009429A1 (en) 2008-02-26 2011-01-13 Paul Oakley Heterocyclic compounds as inhibitors of cxcr2
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之***吡啶化合物
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
TW201444848A (zh) 2009-01-30 2014-12-01 Takeda Pharmaceutical 稠環化合物及其用途
WO2010111712A2 (en) 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
RU2618475C2 (ru) 2010-09-10 2017-05-03 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
EP3323820B1 (en) * 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
WO2013010181A2 (en) 2011-07-14 2013-01-17 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
EP2755962B1 (en) 2011-09-13 2017-03-01 Glaxosmithkline LLC Azaindazoles
BR112014007603A2 (pt) 2011-09-30 2017-06-13 Glaxosmithkline Llc métodos de tratamento do câncer
TR201904660T4 (tr) 2012-03-12 2019-05-21 Epizyme Inc İnsan EZH2 inhibitörleri ve bunun kullanım yöntemleri.
CN105189506A (zh) 2012-11-19 2015-12-23 诺华股份有限公司 用于治疗寄生虫疾病的化合物和组合物
WO2014100080A1 (en) 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
US10047163B2 (en) 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
PE20160044A1 (es) 2013-02-11 2016-02-11 Constellation Pharmaceuticals Inc Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
BR112015022604A2 (pt) 2013-03-14 2017-10-24 Genentech Inc usos de um modulador de modificador de cromatina e um antagonista de egfr
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5
KR102396710B1 (ko) 2013-12-30 2022-05-10 어레이 바이오파마 인크. 세린/트레오닌 키나제 저해제
EP3104706B1 (en) 2014-02-11 2022-03-23 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
PL3218329T3 (pl) 2014-11-14 2019-09-30 Basf Se Etery benzylowo-propargilowe jako inhibitory nitrifikacji
PT3033944T (pt) 2014-12-16 2018-05-14 Omya Int Ag Carbonato de cálcio para proteção de plantas
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences
CA2969090C (en) * 2014-12-23 2023-05-02 Novartis Ag Triazolopyrimidine compounds and uses thereof

Also Published As

Publication number Publication date
JP2019522051A (ja) 2019-08-08
RU2019101220A (ru) 2020-07-21
SA518400704B1 (ar) 2022-11-03
CN109563100A (zh) 2019-04-02
CL2020002277A1 (es) 2021-02-12
IL263429B (en) 2022-08-01
EP3472168B1 (en) 2024-01-10
US11091489B2 (en) 2021-08-17
KR102519922B1 (ko) 2023-04-11
CA3027246A1 (en) 2017-12-28
CN109563100B (zh) 2021-08-27
EP3472168A1 (en) 2019-04-24
KR20190020753A (ko) 2019-03-04
MX2018016331A (es) 2019-05-20
WO2017219948A1 (en) 2017-12-28
US11548897B2 (en) 2023-01-10
RU2754856C2 (ru) 2021-09-08
US20210340152A1 (en) 2021-11-04
JP7042812B2 (ja) 2022-03-28
RU2019101220A3 (pt) 2020-10-28
CL2018003734A1 (es) 2019-02-15
EP3472168A4 (en) 2019-12-11
IL263429A (en) 2018-12-31
AU2017282871B2 (en) 2020-03-05
AU2017282871A1 (en) 2018-12-20
US20190211022A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
BR112018076443A2 (pt) formas cristalinas de um composto de triazolopirimidina
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
BR112016028773A2 (pt) processos para preparação de compostos antivirais
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
ECSP16088985A (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este
BR112017023950A2 (pt) processo para a preparação de limonen-4-ol
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
CO2017001884A2 (es) Polimorfos de selinexor
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
UY37018A (es) Inhibidores bicíclicos de pad4
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
ECSP17075386A (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
CL2017001046A1 (es) Inhibidoes del bromodominio
CL2017000152A1 (es) Derivados de isoindolinona
CR20170005A (es) Derivados de insoindolina
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
CL2017000151A1 (es) Derivados de piridona
CR20170050A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112017028493A2 (pt) uso de cepas microbacterianas para a produção de agentes antibacterianos
BR112017008854A2 (pt) partículas de cadotrila
CL2018002756A1 (es) Un proceso mejorado para la preparación de tartrato de butorfanol.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]